Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE) (DREPAGLOBE)

• ClinicalTrials.gov Identifier: NCT03964792
• Recruitment Status: Active, not recruiting
• First Posted: May 28, 2019
• Last Update Posted: September 27, 2022
• Sponsor: Assistance Publique - Hôpitaux de Paris
• Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris

Tracking Information

• First Submitted Date: May 14, 2019
• First Posted Date: May 28, 2019
• Last Update Posted Date: September 27, 2022
• Actual Study Start Date: November 12, 2019
• Actual Primary Completion Date: July 28, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 24, 2019)

• Incidence of transplant related mortality [ Time Frame: up to 100 days post treatment ]
  To evaluate the procedure safety
• Incidence of the need for rescue autologous bone marrow transplant [ Time Frame: up to 100 days post treatment ]
  To evaluate the procedure safety
• Frequency and severity of AEs post transplant transplant [ Time Frame: 6 months post-transplant ]
  Based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the procedure safety
• Incidence of vector-derived Replication competent lentivirus (RCL) [ Time Frame: 6 months post-transplant ]
  To evaluate the procedure safety
• Incidence of clinically detectable malignancy and/or abnormal clonal dominance assessed as related to study treatment [ Time Frame: 6 months post-transplant ]
  To evaluate the procedure safety.It will be evaluated by vector insertion site analysis (VISA.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 24, 2019)

• Concentration of neutrophil [ Time Frame: 6 months post-transplant ]
  To evaluate the efficacy
• Concentration of platelet [ Time Frame: 6 months post-transplant ]
  To evaluate the efficacy. It will be quantified by High performance liquid chromatography
• Percentage HbAS3 [ Time Frame: 6 months post-transplant ]
  To evaluate the efficacy. It will be quantified by High performance liquid chromatography It will be quantified by High performance liquid chromatography
• Frequency and severity of adverse events [ Time Frame: 24 months post-transplant ]
  based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the long -term safety
• Absence of RCL (Replication competent lentivirus) [ Time Frame: 24 months post-transplant ]
  To evaluate the long -term safety
• Absence of clinically detectable malignancy or abnormal clonal dominance assessed as related to study treatment [ Time Frame: 24 months post-transplant ]
  To evaluate the long -term safety. It will be evaluated by vector insertion site analysis (VISA).
• Protein expression through percentage of anti-sickling Hb [ Time Frame: 24 months post-transplant ]
  To evaluate the long -term efficacy

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)
• Official Title: A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients With Sickle Cell Disease (SCD)
• Brief Summary: The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3 globin gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients with Sickle Cell Disease (SCD)
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Sickle Cell Disease

Intervention

Genetic: DREPAGLOBE drug product

Each patient will receive a single IV infusion of DREPAGLOBE drug product

Study Arms

Experimental: DREPAGLOBE drug product

The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.

Intervention: Genetic: DREPAGLOBE drug product

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: September 26, 2022): 6
• Original Estimated Enrollment (submitted: May 24, 2019): 10
• Estimated Study Completion Date: January 2024
• Actual Primary Completion Date: July 28, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• - Age 12-20 years
• Diagnosis of HbSS or S-beta zero thalassemia by Hb electrophoresis or genetic analysis.

• Clinical history or ongoing evidence of severe sickle cell anemia with one OR more of the following clinical complications demonstrating disease severity:

  • At least 3 vaso occlusive crises requiring hospitalization, under hydroxyurea or transfusion, within 2 years prior to enrollment
  • One severe acute chest syndrome (ACS) hospitalized in intensive care unit
  • At least 2 episodes of ACS within the prior 3 years), including one under HU.
  • Acute priapism (at least 2 episodes > 3h in the preceding year or in the year prior to the start of a regular transfusion program), OR stuttering priapism ≥ 1 by week under sickle cell treatment (HU, transfusion or phlebotomy).
  • Cerebral vasculopathy confirmed by MRA (magnetic resonance angiography) without Moya-moya
  • Presence of sickle cell cardiomyopathy documented by Doppler echocardiography (left ventricular ejection fraction (LVEF) <55% AND tricuspid regurgitation velocity >2.5m/s on cardiac echocardiograph),
  • Tricuspid regurgitation velocity >2.8m/s on cardiac echocardiograph without pulmonary hypertension confirmed by right heart catheterization (mPAP<25mmHg)
• Failed hydroxyurea (HU) therapy, were unable to tolerate HU therapy, or, if 18 years of age or older, have actively made the choice to not take the recommended daily HU regimen. Inadequate clinical response to HU, defined as any one of the following outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crises requiring hospitalization, no rise in Hb >1.5 gm/dl from pre-HU baseline or requires transfusion to maintain Hb > 6.0 gm/dL, had an episode of ACS despite adequate supportive care measures.
• Karnovsky/Lansky performance score ≥ 60%
• Sexually active patients must be willing to use an acceptable method of double-barrier contraception for at least 12 months post-infusion (beyond 12 months at the discretion of the investigator)

Exclusion Criteria:

• Chromosomal (karyotyping) or molecular anomalies (detected by NGS) ( ie 7 chromosomal monosomy)
• Existence of a matched sibling donor
• Patients who have started new treatment for SCD within 6months of enrollment
• Hematologic evaluation: Leukopenia (WBC < 3000 µL) ( en cours) or neutropenia (ANC < 1000 µL) or thrombocytopenia (platelet count < 100,000 µL) (not due to an erythropheresis procedure)
• PT/INR or PTT > 1.5 times upper limit of normal (ULN) or clinically significant bleeding disorder
• Evaluations within 6 months prior to screening visit:
• ALT or AST > 3 times ULN
• Liver Cirrhosis suspicion on echography, CT scan or MRI AND confirmed by histology
• Cardiac evaluation: LVEF < 40% by cardiac echocardiogram or by MUGA scan
• Stroke with significant CNS sequelae i.e., Rankin > 2
• Lung interstitial infiltrate AND Forced Vital Capacity less than 70% AND DLCO less than 60% at steady state
• Confirmed pulmonary hypertension defined by a right heart catheterization (PAPm>25mmHg). Right heart catheterization is required if tricuspid regurgitation velocity >2.8m/s on cardiac echocardiograph OR >2.5m/s with an abnormal Brain Natriuretic Peptide dosage or an important decrease in transcutaneous Hb O2 saturation during the 6 minutes walk test.
• Seropositivity for HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HTLV-1 (Human T-Lymphotropic Virus), or active Hepatitis B Virus, or active infection by CMV or parvovirus B19, based on positive blood PCR.
• Pregnancy or breastfeeding in a postpartum female
• Any current cancer or prior history of a malignant disease, with the exception of curatively treated non-melanoma skin cancer
• Immediate family member with an established or suspected Familial Cancer Syndrome
• Diagnosis of significant psychiatric disorder of the subject that could seriously impeded the ability to participate in the study
• Patients who failed previous HSCT and are severely ill
• Any clinically significant active infection
• Participation in another clinical study with an investigational drug within 30 days of screening
• Any condition, based on perspective of the medical monitor and treating investigator, which may lead to increased safety risk or inability to comply with the protocol

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 12 Years to 20 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France

Administrative Information

• NCT Number: NCT03964792
• Other Study ID Numbers: P170006J
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Assistance Publique - Hôpitaux de Paris
• Original Responsible Party: Same as current
• Current Study Sponsor: Assistance Publique - Hôpitaux de Paris
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Pablo BARTULOCCI, MD & PhD; Department of internal medicine, Henri-Mondor Hospital, Creteil, France.

• PRS Account: Assistance Publique - Hôpitaux de Paris
• Verification Date: September 2022